24/09/2026 US FDA approves belzutifan + lenvatinib in post-IO advanced ccRCC based on PFS superiority over cabozantinib, despite no statistically significant OS benefit CSPC reports positive Phase III results for becotatug + osimertinib, demonstrating significant PFS benefit and favorable OS trend in first-Line EGFR Exon20ins NSCLC US FDA approves belzutifan + lenvatinib in post-IO advanced ccRCC based on PFS superiority over cabozantinib, despite no statistically significant

Renal cell carcinoma (RCC) stands as the predominant form of kidney cancer, comprising about 90% of kidney cancer cases. It accounts for roughly 3% of all cancer diagnoses, with a notably higher occurrence in Western countries, likely linked to the increased detection of small renal masses. Despite advancements in targeted therapies and immunotherapies, the prognosis for stage IV RCC remains challenging, with a 5-year survival rate of only 17%. Furthermore, non-clear cell RCC